Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evalueringen av stoffet R3R01 for utskillelse av protein i urinen hos pasienter med diabetisk nyresykdom. (Kidney ABC)

18. september 2026 oppdatert av: River 3 Renal Corp.

Effekter av ABCA1 Inducer R3R01 på albuminurinivåer ved diabetisk nyresykdom

The goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 years of age) with type 2 diabetes and resulting kidney disease.

The main questions it aims to answer are:

  1. Does 3 months of treatment with 200mg of the drug R3R01 morning and evening have a beneficial effect on the amount of protein excreted in the urine in patients with type 2 diabetes and kidney disease?
  2. Does R3R01 have an effect on kidney function and daily blood pressure?

Researchers will compare the results of 40 people who take R3R01 to 20 people who receive an inactive substance (placebo).

Participants will receive R3R01 or the placebo as an oral tablet and undergo a selection of medical examinations - such as:

  • blood samples
  • urine tests
  • kidney tests involving a radiolabelled marker which is injected into the bloodstream and monitored via blood samples
  • 24 hour blood pressure monitoring via a wearable device
  • urine pregnancy test (if applicable)

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

An increasing amount of evidence suggests that lipid dysmetabolism and accumulation in the kidneys play a central role in the pathogenesis of kidney disease. This lipotoxicity, in turn, may contribute to the development of albuminuria and chronic kidney disease.

One may surmise that interventions that reduce or prevent the progression of kidney lipid accumulation protect against the progression of kidney disease, including diabetic kidney disease (DKD). Therefore, it is possible inhibiting cholesterol absorption, might effectively protect against lipid accumulation and related disease in the kidneys.

R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney.

Persons with type 2 diabetes with moderate and severe albuminuria have a poor renal and cardiovascular prognosis. As albuminuria is viewed both as a risk marker but also as a target for intervention, any treatment with antiproteinuric effects could be beneficial. The role of ABCA1 inducer treatment on kidney parameters in diabetic kidney disease is not known. By investigating the impact of ABCA1 inducer treatment on albuminuria, it will be determined whether this intervention may represent a future treatment option.

This study is a single center, double-blind, placebo controlled, parallel group randomized (2:1) study, in 60 people with type 2 diabetes with moderate or severe albuminuria and estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73m2. 40 people will take R3R01 whilst 20 people receive the placebo.

The study's primary objective is to evaluate the effect of 12 weeks treatment with R3R01 on albuminuria in the study population. In addition to a 12 week treatment period, there will be a follow-up period of approximately 24 weeks (168 days). The expected total duration of study participation is up to 36 weeks for each patient.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Copenhagen
      • Copenhagen, Copenhagen, Danmark, 2730
        • Rekruttering
        • Steno Diabetes Center Copenhagen
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Adults (above 18 years of age) with controlled type 2 diabetes (hemoglobin A1c less than 10.5%).
  2. Stable antihypertensive treatment 4 weeks before start of study drug and throughout study duration.
  3. Titrated to the maximal dose or maximal tolerated dose of renin-angiotensin blocking treatment.
  4. Stable treatment with lipid lowering agents for at least 4 weeks.
  5. People on SGLT2-Inhibitors should be on a stable dose of the drug for at least 3 months.
  6. UACR >30 mg/g and < 5000 mg/g on two consecutive measurements.
  7. eGFR >30 ml/min/1.73 m2 (CKD-EPIcrea formula).
  8. Abdominal obesity Women: > 80 cm, Men: > 95 cm or fasting triglyceride >2.0 mmol/l.
  9. Systolic blood pressure ≥110 mmHg and ≤160 mmHg.
  10. Both female patients, as well as female partners of male patients who are of child-bearing potential must be willing to not become pregnant for the complete duration of the study and 90 days after the last dose of study medication.
  11. Males (including sterilized subjects) whose female partners have child-bearing potential, must agree to use male contraception (condoms) during the period from the time of signing the informed consent form through 90 days after the last dose of study drug. They must agree to immediately inform the investigator if their partner becomes pregnant during the study.

Exclusion Criteria:

  1. Polycystic kidney disease, ANCA-associated vasculitis, or lupus nephritis.
  2. Ongoing cancer treatment.
  3. Immunosuppressive therapy or immunosuppression the prior 6 months.
  4. Nephrotic syndrome.
  5. Impaired liver function (clinically significant).
  6. Pregnancy or lactation.
  7. Failure to understand patient information or to collaborate with the investigator.
  8. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study unless they agree to use highly effective contraception.
  9. History of hypersensitivity to study drug and/or any of its excipients.
  10. Hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
  11. Active or planned treatment with a medication that interacts with R3R01.
  12. Any other medical condition(s) that might put the patient at risk or influence study results in the investigators opinion, or that the investigator deems unsuitable for the study including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: R3R01

R3R01 oral tablet (200 mg twice daily) for 12 weeks

R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.

Placebo komparator: Placebo

Placebo oral tablet twice daily for 12 weeks

Please refer to arm/group description for further information.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Urinary albumin-to-creatinine ratio (UACR)
Tidsramme: 12 weeks (84 days)

Urinary albumin-to-creatinine ratio (UACR) (Change from baseline to end of treatment at 12 weeks (84 days).

12 weeks (84 days)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Measured or Estimated Glomerular Filtration Rate
Tidsramme: 12 weeks (84 days)

Measured glomerular filtration rate (GFR) with plasma clearance of 99Tc-DTPA or eGFR measured with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on creatinine and/or cystatin C (change from baseline to end of treatment at 12 weeks (84 days)).

12 weeks (84 days)
24 hours ambulatory blood pressure
Tidsramme: 12 weeks (84 days)

24 hours ambulatory blood pressure (change from baseline to end of treatment at 12 weeks (84 days)).

12 weeks (84 days)
Plasma Pharmacokinetics
Tidsramme: 24 weeks (168 days)

R3R01 plasma concentrations will be measured to determine Maximum plasma concentration (Cmax)

24 weeks (168 days)
Plasma Pharmacokinetics
Tidsramme: 24 weeks (168 days)

R3R01 plasma concentrations will be measured to determine minimum blood plasma concentration (Cmin)

24 weeks (168 days)
Plasma Pharmacokinetics
Tidsramme: 24 weeks (168 days)

R3R01 plasma concentrations will be measured to determine the half-life (T1/2)

24 weeks (168 days)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Peter Rossing, dr.med., Steno Diabetes Center Copenhagen

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. oktober 2024

Primær fullføring (Antatt)

1. april 2027

Studiet fullført (Antatt)

1. april 2027

Datoer for studieregistrering

Først innsendt

4. september 2024

Først innsendt som oppfylte QC-kriteriene

13. september 2024

Først lagt ut (Faktiske)

19. september 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere